Either by oral ingestion as salt or as an adjuvant, Al exposure may
induce the dysfunction or activation of glial cells that are important in
maintaining the homeostasis of the CNS and in neurodevelopment
(Morris et al., 2017). Furthermore, Al can induce the activation of
microglia to produce TNF-α, IL-6, iNOS, NOS-2, neuroinflammatory
PICs and ROS (Zaky et al., 2013). The microglia may govern the regulation
of neurogenesis and neurodevelopmental factors and interfere
with synaptic pruning and with the proliferation of neurons, which in
turn, may lead to the development of ASD (Kettenmann et al., 2013;
Edmonson et al., 2016; Hoeijmakers et al., 2016).
Aluminum in the Brain in Multiple Sclerosis: Regulatory and Funding Agencies Silent, Complicit
In a new case series study, brain tissue from 14 donors with a diagnosis of MS was studied in a case series by Mold et al (2018) using transversely heated graphite furnace atomic absorption spectrometry. The study found high aluminum content (>10 ug/g dry weight) in all areas of the brain studied, with some areas exceeding 50 ug/g.
Elevated brain aluminium, early onset Alzheimer’s disease in an individual occupationally exposed to aluminium
While aluminum is a known neurotoxin and occupational exposure to aluminum has been implicated in neurological disease, including Alzheimer’s disease, this finding is believed to be the first record of a direct link between Alzheimer’s disease and elevated brain aluminum following occupational exposure to the metal.Feb 12, 2014
In February 2018, the FDA and CDC approved the recommendation for a new hepatitis B vaccine, Heplisav-B targeting adults over the age of 18. The U.S. Food and Drug Administration (FDA) had twice rejected the application for licensure for Heplisav-B in the past four years because of safety signals. Heplisav-B differs from other licensed hepatitis B vaccines in that it contains a new synthetic adjuvant known as cytosine phosphoguanine 1018 (CpG 1018) composed of short synthetic DNA molecules. In 2016, the FDA rejected an application for licensure for the Heplisav-B vaccine, because the agency was concerned about an increased rate of heart attacks and deaths in people who had been given the vaccine. During the trial, approximately 14 subjects had heart attacks. In July 2017, the FDA committee convened to re-evaluate the scientific evidence and make a decision on whether Heplisav B should or should not be approved for use in the U.S. This committee had only one cardiologist on the team, Milton Packer, MD, who is a distinguished scholar in cardiovascular science at the Baylor University Medical Center in Dallas, Texas. According to Dr. Packer, it was possible that the Heplisav B vaccine’s novel adjuvant was related to the higher number of heart attacks in study participants who received the experimental vaccine. He stated: “To know if the 7 -1 heart attack imbalance represented a real risk, we’d need comparative data in 50,000 people.” However, the only way to conduct such a large trial would be to approve the vaccine and see what happens in the public. With Dr. Packer abstaining in his vote to recommend the vaccine, the FDA committee approved it anyway. Dr. Packer stated: “Why did I abstain? Based on the available data, it was impossible for anyone to know if the increase in heart attack risk was real. There is a simple rule in life: if you don’t know, you should say you don’t know.” The vaccine is now available to the public, and all those who receive it are basically guinea pigs to find out if heart attacks will result from the experimental vaccine, and if it will continue to have FDA approval.
Non-invasive therapy to reduce the body
burden of aluminium in Alzheimer’s disease
Abstract. There are unexplained links between human exposure to aluminium and the incidence, progression and aetiology of Alzheimer’s disease. The null hypothesis which underlies any link is that there would be no Alzheimer’s disease in the effective absence of a body burden of aluminium. To test this the latter would have to be reduced to and retained at a level that was commensurate with an Alzheimer’s disease-free population. In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium. This same mechanism might now be applied to both the removal of aluminium from the body and the reduced entry of aluminium into the body while ensuring that essential metals, such as iron, are unaffected. Based upon the premisethat urinary aluminium is the best non-invasive estimate of body burden of aluminium patients with Alzheimer’s disease were asked to drink 1.5 L of a silicic acid-rich mineral water each day for five days and, by comparison of their urinary excretion of aluminium pre-and post this simple procedure, the influence upon their body burden of aluminium was determined. Drinking the mineral water increased significantly (P <0.001) their urinary excretion of silicic acid (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol
creatinine) and concomitantly reduced significantly (P = 0.037) their urinary excretion of aluminium (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). The latter was achieved without any significant (P >0.05) influence upon the urinary excretion of iron (20.7 ± 9.5 to 21.7 ± 13.8 nmol/mmol creatinine). The reduction in urinary aluminium supported the future longer-term
use of silicic acid as non-invasive therapy for reducing the body burden of aluminium in Alzheimer’s disease.
First Experimental Study on Baby Mice Finds Autism-like Response to Common Vaccine Ingredient
A breakthrough study by scientists from the University of British Columbia in Vancouver, Canada has been published in the Journal of Inorganic Biochemistry demonstrating that significant correlations exist between rates of Autism Spectrum Disorder (ASD) and total aluminum adjuvants given to children through vaccines in several Western countries.
This is the first experimental study to demonstrate that aluminum adjuvants can impair social behavior if applied in the early period of postnatal development.
An infant in the United States, in its first two years, usually receives 27 vaccines as part of the routine pediatric vaccination schedule; many of which contain aluminum adjuvants.
On Day 1 of life, infants receive 17 times more aluminum than would be allowed if doses were adjusted per body weight.
FDA regulations require safety testing of constituent ingredients in drugs (21 CFR 610.15). With the exception of extraneous proteins, no component safety testing is required for vaccines or vaccine schedules. The dosing of aluminum in vaccines is based on the production of antibody titers, not safety science. Here we estimate a Pediatric Dose Limit that considers body weight. We identify several serious historical missteps in past analyses of provisional safe levels of aluminum in vaccines, and provide updates relevant to infant aluminum exposure in the pediatric schedule considering pediatric body weight
The small quantity of aluminum retained in the body
accumulates over time. Most of the aluminum that accumulates
(50 to 60 percent) settles in the bones, some in the lungs (about 25
percent) and some in the brain (about 1 percent). The remaining
quantities are distributed in serum, skin, gastrointestinal tract, lymph
nodes and glands. In fact, low quantities of aluminum can be found
in most organs.
VLA comment: Apparently it is okay with the CDC and Paul Offit at the Philadelphia Children’s Hospital that…and I quote and excerpt…the process which a small infant has to deal with excreting this poison or the consequences of retain the metal in the bones or the brains is inconsequental:
Pharmacokinetics and Differential Regulation of Cytochrome P450 Enzymes in Type 1 Allergic Mice
“We investigated hepatic P450 metabolism and drug pharmacokinetics in type 1 allergic mice induced by ovalbumin (OVA) emulsified with aluminum and inactive Bordetella pertussis. To further propose a possible key factor in drug-allergic disease interactions, we examined the inhibitory effect of NO, a marker of allergic conditions on the activities of major P450 isoforms”.
VLA COMMENT-CD RE: FLUORIDE: There may be a miniscule amount of natural fluoride that exists in the soils and is released just like other minerals. I wonder FLUORIDE being less toxic in its natural state than the much more reactive state that is in the fluoride compounds added to water. I have only seen positive effects from people drinking Fiji water – the benefits of getting rid of the aluminum are so great, and I see it as a time/toxicity equation. That a 3-6 month intensive course of Fiji water to lower the body burden of aluminum is of such benefit, that it does not need to be consumed forever to reap benefits, and there are other likely ways to protect against any miniscule fluoride exposure (like taking vitamin c and other antioxidants) that it is worth consuming it if aluminum toxicity is suspected. Our studies show that ALL people with a level of greater than 1mcg/g of dry brain weight have pathology that is associated with Alzheimer’s, or autism (depending on the age) and no brains examined with these levels were healthy. All healthy brains had less than 1 mcg of aluminum per gram of dry brain weight. It is not debatable anymore.
In addition, people with the aggressive form of MS excreted far more aluminum in their urine than healthy people, and when their aluminum body burden was reduced by drinking silica rich mineral water, they did not have any progression of their disease. The study was not designed to measure improvement in their condition, but we would have likely seen improvement if the study was designed with that outcome. A facebook group has formed called Fiji Water Detox and Epilepsy support Group and parents are reporting that their children are stopping or drastically reducing the number of seizures per day when consuming Fiji water (sometimes the kids had hundreds of seizures a day which stopped overnight when they started drinking Fiji). The benefits far outweigh any risks, and getting the aluminum out should be the highest priority for anyone dealing with a chronic, complex, inflammatory health problem.